Ondine Biomedical (LON:OBI) Trading 3.8% Higher - Here's Why

Key Points

• Ondine Biomedical's stock price increased by 3.8%, reaching C$13.50 after trading as high as C$14.00, with trading volume up 46% compared to the average.
• The company, focused on innovative photodisinfection-based therapies to combat serious infections, has a market cap of C$97.07 million and a P/E ratio of -4.07.
• Ondine Biomedical maintains a robust financial position with a debt-to-equity ratio of 25.95 and a quick ratio of 8.26, indicating strong liquidity.

Ondine Biomedical Inc. (LON:OBI - Get Free Report)'s stock price rose 3.8% during mid-day trading on Monday . The stock traded as high as C$14.00 and last traded at C$13.50. Approximately 373,028 shares were traded during trading, an increase of 46% from the average daily volume of 254,635 shares. The stock had previously closed at C$13.00.

Ondine Biomedical Stock Performance

The firm has a market capitalization of C$104.26 million, a PE ratio of -4.37 and a beta of 0.10. The company has a quick ratio of 8.26, a current ratio of 1.36 and a debt-to-equity ratio of 25.95. The company has a 50-day moving average of C$12.92 and a 200 day moving average of C$11.04.

About Ondine Biomedical

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens. Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.